课题基金 / 基金详情

Empowering Cancer Patient-Provider Communication: A Personal Virtual Assistant for Automated Post-Discharge Engagement

Empowering Cancer Patient-Provider Communication: A Personal Virtual Assistant for Automated Post-Discharge Engagement
增强癌症患者与提供者的沟通:用于出院后自动参与的个人虚拟助理
批准号:
10831223
负责人:
HELEN E HESLOP
金额:
$9.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-07-01 至 2025-06-30
关键词:
AddressAdherenceAdoptionAdverse eventAgreementAnxietyAttitudeCancer PatientCaringCenter Core GrantsCessation of lifeClinicalCollaborationsCommunicationComplexComprehensive Cancer CenterComputersControl GroupsDataDevicesEarly identificationEffectivenessEffectiveness of InterventionsEligibility DeterminationEnsureExerciseFosteringFoundationsFrequenciesFundingGoalsGrantHandHealthHealth PersonnelHealth Services AccessibilityHospitalizationHospitalsImprove AccessIndividualIndustryInfectionInstructionInterventionInterviewJudgmentMalignant NeoplasmsManaged CareMental DepressionModelingMonitorOncologistOncologyOperative Surgical ProceduresOutcomeParticipantPatient CarePatientsPharmaceutical PreparationsPilot ProjectsPopulation SciencesProviderQuality of CareQuestionnairesRandomizedRandomized, Controlled TrialsRecurrent Malignant NeoplasmResourcesRiskSamplingScienceStressStretchingSymptomsSystemTabletsTechnologyTelephoneTimeUniversitiesUpdateVoiceacceptability and feasibilityadverse event riskcancer preventioncancer recurrencecare coordinationcare fragmentationcare providersclinical efficacycomparison controldesigndiariesdigitaleffectiveness validationempowermentfollow-upgroup interventionhospital carehospital readmissionimprovedintelligent personal assistantinterestmembermortalitymultidisciplinarynew technologypatient orientedpatient-clinician communicationpersonalized carephysical symptompreventprogramsprovider adherencepsychological symptomresponseshared decision makingstress reductionsuccesssymptom managementtreatment planninguser-friendlyvalidation studiesweb portal

项目摘要

项目成果

HELEN E HESLOP的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract This application is submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-23-041. Inadequate communication between patients and providers following hospital discharge poses a significant challenge for oncology patients. The complex, multidisciplinary care these patients require often results in insufficient follow-up and misunderstandings of treatment plans, leading to increased anxiety, stress, and reduced compliance. This in turn elevates the risk of hospital readmission, cancer recurrence, heightened suffering, and even mortality. To address these issues, our team has collaborated with the Dan L Duncan Comprehensive Cancer Center (DLDCCC), supported by a P30 grant, to develop an AI-based Personal Virtual Assistant (PVA) designed to enhance the frequency, quality, and timeliness of patient-provider communication. The PVA is a hands-free, voice-activated AI-driven system that utilizes care plan data for both patients and healthcare providers, fostering continuous communication. The PVA comprises: 1) a voice-enabled, user-friendly AI kiosk-based interactive tablet that presents patients with essential plan details, such as reviewing discharge instructions, receiving post-discharge reminders (e.g., medication, care tasks), providing guidance for exercise and stretching therapy, and facilitating bi-directional messaging with clinical staff; and 2) a comprehensive web portal that enables care providers to monitor compliance, modify patient-centered multidisciplinary care plans, engage in shared decision-making, and remotely update the PVA tablet to prevent care overlap. The web portal can be accessed through any computer, tablet, or phone app. Our pilot study has demonstrated the feasibility and acceptability of the PVA among oncology patients and clinical experts. Building on this preliminary data, we propose a supplemental grant to further assess the PVA's feasibility, scalability, and proof-of-concept effectiveness in enhancing patient-provider communication and adherence to care plans. We will conduct a pilot randomized controlled trial (RCT) with 20 oncology patients undergoing surgical procedures to evaluate the improvement of communication, acceptability, and scalability of the PVA, as well as its effectiveness in reducing post-discharge adverse events. This supplemental grant will help establish the necessary power for clinically validating the PVA's acceptance and effectiveness in mitigating adverse events associated with inadequate patient-provider communication.
期刊论文(431)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s11060-020-03599-1
发表时间: 2020-09
期刊: Journal of neuro-oncology
影响因子: 3.9
作者: [Khan AB, Gadot R, Shetty A, Bayley JC 5th, Hadley CC, Cardenas MF, Jalali A, Harmanci AS, Harmanci AO, Wheeler DA, Klisch TJ, Patel AJ]
通讯作者: Patel AJ
DOI: 10.1158/1078-0432.ccr-20-2961
发表时间: 2021-05-01
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者: [Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS]
通讯作者: Wang XS
DOI: 10.18632/oncotarget.17532
发表时间: 2017-08-15
期刊: Oncotarget
影响因子: --
作者: [Wu H, Bi J, Peng Y, Huo L, Yu X, Yang Z, Zhou Y, Qin L, Xu Y, Liao L, Xie Y, Conneely OM, Jonkers J, Xu J]
通讯作者: Xu J
DOI: 10.3389/fpsyg.2018.01780
发表时间: 2018
期刊: Frontiers in psychology
影响因子: 3.8
作者: [Badr H, Herbert K, Bonnen MD, Asper JA, Wagner T]
通讯作者: Wagner T
268
    Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
    • 批准号:
      9069027
    • 项目类别:
    • 资助金额:
      $16.02万
    • 财政年份:
      2011
    • 负责人:
      HELEN E HESLOP
    • 依托单位:
    Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
    • 批准号:
      8479213
    • 项目类别:
    • 资助金额:
      $16.02万
    • 财政年份:
      2011
    • 负责人:
      HELEN E HESLOP
    • 依托单位:
    MOST CLOSELY HLA MATCHED ALLOGENEIC VIRUS SPECIFIC CYTOTOXIC T-LYMPHOCYTES (CTL)
    • 批准号:
      8356704
    • 项目类别:
    • 资助金额:
      $0.2万
    • 财政年份:
      2010
    • 负责人:
      HELEN E HESLOP
    • 依托单位:
    CLINICAL TRIAL: ADMINISTRATION OF EBV SPECIFIC CYTOTOXIC T LYMPHOCYTES TO RECIPI
    • 批准号:
      8356760
    • 项目类别:
    • 资助金额:
      $0.12万
    • 财政年份:
      2010
    • 负责人:
      HELEN E HESLOP
    • 依托单位:
    海外基金